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Abstract 
Review on Pediatric-type Follicular Lymphoma with 
data on clinics, and the genes involved. 
Clinics and pathology 
Disease 
Pediatric-type follicular lymphoma (pFL), which 
was formerly a provisional diagnosis under follicular 
lymphoma, is a newly recognized entity in the 2016 
WHO classification (Swerdlow et al., 2016). It is an 
extremely rare nodal B-cell lymphoma occurring 
predominantly in the pediatric and young-adult 
population, which shows unique characteristics 
distinct from the more common follicular lymphoma 
seen in adults (Louissaint et al., 2012). 
Phenotype/cell stem origin 
pFL is a proliferation of follicle center B-cells with 
often blastoid morphologic features. The B-cells 
typically express markers of germinal center B-cells, 
including CD10, BCL6, human germinal center-
associated lymphoma (HGAL) and Lim domain only 
2 (LMO2) (Liu et al., 2013; Karnik et al., 2015). The 
neoplastic cells largely lack BCL2 protein 
expression, or if it is expressed show only dim or 
partial expression. Importantly, the characteristic 
IGH - BCL2 t(14;18)(q32;q21) translocation, seen in 
follicular lymphomas of adults, is absent. The 
proliferation index is elevated (>30%) as assessed by 
Ki67. 
Epidemiology 
Pediatric-type follicular lymphoma is a rare disease 
with incidence estimates of approximately 5% of all 
childhood lymphomas (O'Suoji et al., 2016). The age 
of presentation is between the ages of 3 and 18 years 
of age, though cases observed in early adulthood 
have also been described. A male predominance is 
commonly seen. 
Clinics 
pFL typically is localized to lymph nodes within the 
cervical region although extranodal sites including 
the testis, epididymis and gastrointestinal tract do 
occur. The vast majority of patients present with 
localized involvement without systemic disease and 
follow an indolent clinical course. 
Pathology 
Histologically, lymph nodes show effacement of 
normal architecture by a proliferation of expansile, 
ill-defined follicles with attenuated mantle zones 
(figure 1). The atypical follicles are comprised of a 
mixture of intermediate and larger-sized 
centroblastic lymphocytes with more immature 
chromatin often lending to an interpretation of 
higher-grade cytology and aggressive disease. 
Notably, these morphologic features are often not 
entirely specific and can show overlap with other 
lymphomas including pediatric marginal zone 
lymphoma (Quintanilla-Martinez et al., 2016). By 
the 2016 WHO classification, diffuse areas 
suggesting progression or transformation, exclude a 
diagnosis of pFL. 
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Figure 1: Morphologic features of pediatric-type follicular lymphoma. Irregularly shaped enlarged follicles with abnormal mantle 
zones are seen at low power (40X). High power magnification illustrates the cytomorphology of neoplastic cells which have more 
blastoid chromatin and irregular nuclear contours, inset (1000X). 
 
Treatment 
Patients presenting with localized disease respond to 
surgical resection without further intervention. 
Historically, additional management strategies have 
included surgical excision with chemotherapy with 
or without local radiation (Attarbaschi et al., 2013). 
Prognosis 
Prognosis is similar to other indolent lymphomas, 
with excellent progression free and overall survival. 
The vast majority of patients achieve complete 
remission and show no evidence of disease 
following local surgical treatment or radiation 
therapy. 
 
Cytogenetics 
Cytogenetics morphological 
Recurrent cytogenetic abnormalities are not 
common in pFL. BCL2, BCL6, and MYC 
rearrangements are absent. Recurrent deletion or 
copy number-neutral loss of heterozygosity (LOH) 
at 1p36 have been described, and these alterations 
are associated with TNFRSF14 mutations (Martin-
Guerrero et al., 2013). 
Cytogenetics molecular 
The mutational landscape of pFL is not well 
understood. TNFRSF14 mutations have been  
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reported in association with, as well as distinct from 
1p36 deletion or copy number neutral LOH. 
Recently, a recurrent somatic variant encoding 
p.Lys66Arg in the transcription factor interferon 
regulatory factor 8 (IRF8) was described in 3 of 6 
cases of pFL (50%) by whole exome deep 
sequencing (Ozawa et al., 2016).  This point 
mutation was not observed in adult follicular 
lymphoma or cases of pediatric marginal zone 
lymphoma. 
Genes involved and 
proteins 
Note 
While the underlying genetics driving pFL are under 
investigation, recent studies have suggested at least 
two potential pathogenic pathways. 
TNFRSF14 (TNF receptor superfamily 
member 14) 
Location 
1p36.32 
Note 
TNFRSF14 is a member of the TNF (tumor necrosis 
factor) receptor superfamily. In T-cells it is involved 
in signal transduction pathways that activate 
inflammatory and inhibitory immune responses. The 
role of TNFRSF14 in normal B-cell physiology is 
unclear, but it is known to be recurrently deleted or 
show copy number-neutral loss of heterozygosity 
(LOH) along with somatic point mutations in cases 
of pFL. 
IRF8 (interferon regulatory factor 8) 
Location 
16q24.1 
Note 
IRF8 is a member of the IRF family of transcription 
factors contributing to hematopoietic cellular 
differentiation and development, cell cycle 
regulation and apoptosis. Variants in this gene have 
been recently reported in a small percentage of adult 
follicular lymphomas and pediatric-type follicular 
lymphomas. In pediatric-type follicular lymphoma 
the mutations are a specific recurrent mutation, 
p.Lys66Arg, different from mutations in IRF8 which 
are seen in adult follicular lymphomas (Ozawa et al., 
2016). While currently little is known about the 
pathogenic role of IRF8 in this setting, the 
significant portion of pediatric-type follicular 
lymphomas with the same recurrent nucleotide 
change is highly suggestive of a critical alteration 
and potential unique disease origin. 
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